Home › Atopic Dermatitis (Eczema) › NCT05285839

Dupixent and Narrowband UVB for Atopic Dermatitis

Single Center, Pilot Study to Evaluate the Effectiveness and Safety of Dupilumab in Combination With Narrowband UVB (nUVB) Phototherapy in the Treatment of Moderate-to-Severe Atopic Dermatitis

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Male or female adult ≥ 18 years of age;
* Diagnosis of moderate to severe atopic dermatitis as defined at baseline by:

  * EASI score of 16 or greater,
  * IGA score of 3 or greater
  * BSA of 10% or greater,

Exclusion Criteria:

* Subjects with previous exposure to dupilumab.
* Known or suspected hypersensitivity to dupilumab or any of its excipients.
* History of photosensitivity.

About the study

24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.

What is being tested

• Dupixent (drug)

Sponsor: Psoriasis Treatment Center of Central New Jersey · Participants: 40 · Started: Apr 19, 2022

Contact the study team

• Elise Nelson · Phone: 6094434500

Official record on ClinicalTrials.gov — NCT05285839

Locations in the U.S.

Conditions

• Atopic Dermatitis (Eczema)

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.